GANYMED Pharmaceuticals AG announced today that several monoclonal lead antibodies directed against the company’s GC182 cancer target have shown excellent efficacy against solid human tumors in mouse Xenograft models. No toxicity was observed. The results fully confirm earlier experiments, where antibodies directed against GC182 proved to be very effective against cancer cells that expressed the target.
